Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $65,324 | $67,635 | $79,204 | $86,160 |
| % Growth | -3.4% | -14.6% | -8.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $65,324 | $67,635 | $79,204 | $86,160 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $106,740 | $131,476 | $163,524 | $164,522 |
| G&A Expenses | $43,933 | $57,850 | $52,887 | $45,482 |
| SG&A Expenses | $43,933 | $57,850 | $52,887 | $45,482 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $150,673 | $189,326 | $216,411 | $210,004 |
| Operating Income | -$85,349 | -$121,691 | -$137,207 | -$123,844 |
| % Margin | -130.7% | -179.9% | -173.2% | -143.7% |
| Other Income/Exp. Net | $1,800 | $3,903 | $6,212 | $1,656 |
| Pre-Tax Income | -$83,549 | -$117,788 | -$130,995 | -$122,188 |
| Tax Expense | -$1,660 | -$1,743 | $2,821 | -$433 |
| Net Income | -$81,889 | -$116,045 | -$133,816 | -$121,755 |
| % Margin | -125.4% | -171.6% | -169% | -141.3% |
| EPS | -3.84 | -5.48 | -6.38 | -5.91 |
| % Growth | 29.9% | 14.1% | -8% | – |
| EPS Diluted | -3.84 | -5.48 | -6.38 | -5.91 |
| Weighted Avg Shares Out | 21,336 | 21,157 | 20,969 | 20,603 |
| Weighted Avg Shares Out Dil | 21,336 | 21,157 | 20,969 | 20,603 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,481 | $14,770 | $11,360 | $1,573 |
| Interest Expense | $7,681 | $10,940 | $5,148 | $0 |
| Depreciation & Amortization | $5,089 | $2,336 | $2,371 | $2,973 |
| EBITDA | -$70,779 | -$104,512 | -$123,476 | -$119,215 |
| % Margin | -108.4% | -154.5% | -155.9% | -138.4% |